Drug Trial Radar · NCT02682407
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Actual
Start
Mar 10, 2016
Primary completion
Aug 25, 2020
Study completion Aug 25, 2020
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3 Glomerulopathy (C3G) including Dense Deposit Disease. The study will also evaluate Pharmacokinetics (PK), Pharmacodynamics (PD), anti-drug antibody response (ADA), and neutralizing antibodies (NAb) of narsoplimab when administered intravenously and when administered both intravenously and subcutaneously in participants of Asian descent with IgA Nephropathy.
Conditions
- IgAN
- LN
- MN
- C3G
Interventions
OMS721 (narsoplimab)Biological
Biological: narsoplimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE).Time frame: up to 104 weeks
- Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs.Time frame: 38 weeks
- Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels.Time frame: 38 weeks
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Omeros Investigational Site
Denver, Colorado
Omeros Investigational Site
Augusta, Georgia
Omeros Investigational Site
Lawrenceville, Georgia
Omeros Investigational Site
Evergreen Park, Illinois
Omeros Investigational Site
Voorhees Township, New Jersey
Omeros Investigational Site
Flushing, New York
Omeros Investigational Site
San Antonio, Texas
Omeros Investigational Site
Milwaukee, Wisconsin
Omeros Investigational Site
Chai Wan, Hong Kong
Omeros Investigational Site
Hong Kong, Hong Kong
Omeros Investigational Site
Kowloon, Hong Kong
Omeros Investigational Site
Shatin, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.